{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-031942","form_type":"8-K","ticker":"BCAB","cik":"0001826892","company_name":"BioAtla, Inc.","filed_at":"2026-01-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.390615+00:00","generated_at":"2026-05-16T06:04:00.640283+00:00","sec_items":["5.03","5.07","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BioAtla adopts 1-for-50 reverse stock split via merger after Nasdaq policy reversal; delisting risk","bullets":["Issued one share of super-voting Series A Preferred to pass reverse split (100M votes for), then redeemed it for $0.01.","Board chose not to implement reverse split; Nasdaq said super-voting use now violates Rule 5640 without public notice.","Entered merger for 1-for-50 reverse split; requires majority stockholder vote at special meeting.","AIRC confirmed investment in Inversagen AI; BioAtla to receive $5M for 4.375% of SPV common units.","Nasdaq compliance deadline Feb 2; company believes Nasdaq's delays and policy change were in error and harmful."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-031942","json":"https://secwatch.observer/filing/0001193125-26-031942.json","markdown":"https://secwatch.observer/filing/0001193125-26-031942.md","text":"https://secwatch.observer/filing/0001193125-26-031942.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826892/000119312526031942/0001193125-26-031942-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826892/000119312526031942/bcab-20260126.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T06:04:00.640283+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"93eb4ea69bfc9e1d968d0720e98791c0be1396d6","claim":"BioAtla, Inc.: Filed Certificate of Elimination to remove Series A Junior Preferred Stock from the Amended and Restated Certificate of Incorporation (effective 2026-01-30).","evidence_excerpt":"On January 30, 2026, BioAtla, Inc. (the “Company” or “BioAtla”) filed a Certificate of Elimination (the “Certificate of Elimination”) with the Secretary of State of the State of Delaware with respect to the Company’s Series A Junior Preferred Stock, par value $0.0001 per share (the “Series A Junior Preferred Stock”), following the redemption of the one (1) issued and outstanding share of Series A Junior Preferred Stock (the “Series A Preferred Share”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826892/000119312526031942/0001193125-26-031942-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001104659-26-053557","ticker":"CWEN","company_name":"Clearway Energy, Inc.","filed_at":"2026-05-01T23:59:59+00:00","headline":"Clearway Energy eliminates Class A stock; converts all shares to reduced-vote Class C","event_type":"other_material","sec_items":["1.01","3.03","5.03","5.07","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 5.07, 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-053557","json":"https://secwatch.observer/filing/0001104659-26-053557.json","markdown":"https://secwatch.observer/filing/0001104659-26-053557.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1567683/000110465926053557/0001104659-26-053557-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1567683/000110465926053557/tm2613249d1_8k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On January 30, 2026, BioAtla, Inc. (the “Company” or “BioAtla”) filed a Certificate of Elimination (the “Certificate of Elimination”) with the Secretary of State of the State of Delaware with respect to the Company’s Series A Junior Preferred Stock, par value $0.0001 per share (the “Series A Junior Preferred Stock”), following the redemption of the one (1) issued and outstanding share of Series A Junior Preferred Stock (the “Series A Preferred Share”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1826892/000119312526031942/0001193125-26-031942-index.htm","comparable_excerpt":"Following the Class A Conversion, on May 1, 2026, the Company filed with the Delaware Secretary of State a certificate of retirement pursuant to Section 243 of the DGCL (the “Certificate of Retirement”) to retire all shares of Class A common stock converted in the Class A Conversion, which also had the effect of amending the Amended Charter to (i) reduce the total number of authorized shares of Class A common stock from 34,613,853 to zero, (ii) reduce the total number of authorized shares of capital stock of the Company from 2,544,613,853 to 2,510,000,000 and (iii) eliminate from the Amended Charter all references to the Class A common stock (collectively, the “Class A Retirement”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1567683/000110465926053557/0001104659-26-053557-index.htm"}},{"accession":"0001213900-26-051018","ticker":"DMAA","company_name":"Drugs Made In America Acquisition Corp.","filed_at":"2026-05-01T23:59:59+00:00","headline":"SPAC DMAA shareholders approve extension to April 2027; ~28% of shares redeemed for $99.3M","event_type":"other_material","sec_items":["5.03","5.07","8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 5.07, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-051018","json":"https://secwatch.observer/filing/0001213900-26-051018.json","markdown":"https://secwatch.observer/filing/0001213900-26-051018.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2028614/000121390026051018/0001213900-26-051018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2028614/000121390026051018/ea0288774-8k_drugs.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On January 30, 2026, BioAtla, Inc. (the “Company” or “BioAtla”) filed a Certificate of Elimination (the “Certificate of Elimination”) with the Secretary of State of the State of Delaware with respect to the Company’s Series A Junior Preferred Stock, par value $0.0001 per share (the “Series A Junior Preferred Stock”), following the redemption of the one (1) issued and outstanding share of Series A Junior Preferred Stock (the “Series A Preferred Share”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1826892/000119312526031942/0001193125-26-031942-index.htm","comparable_excerpt":"to amend the Company’s Second Amended and Restated Memorandum and Articles of Association (the “ Existing Charter ”) by adopting an amendment to the Existing Charter in the form set forth in Annex A to the Proxy Statement (the “ Extension Amendment ”) which reflects the extension of the date by which the Company must consummate a business combination (the “ Combination Period ”) up to twelve (12) times from April 29, 2026 (the “ Termination Date ”) to April 29, 2027, each by an additional one (1) month","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2028614/000121390026051018/0001213900-26-051018-index.htm"}},{"accession":"0001649739-26-000020","ticker":"BAFN","company_name":"BayFirst Financial Corp.","filed_at":"2026-04-30T23:59:59+00:00","headline":"BayFirst raises $80M in PIPE, reports Q1 loss of $5.7M, names new bank CEO","event_type":"other_material","sec_items":["1.01","3.02","5.03","2.02","5.02","7.01","8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 7.01, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001649739-26-000020","json":"https://secwatch.observer/filing/0001649739-26-000020.json","markdown":"https://secwatch.observer/filing/0001649739-26-000020.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649739/000164973926000020/0001649739-26-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649739/000164973926000020/bafn-20260428.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On January 30, 2026, BioAtla, Inc. (the “Company” or “BioAtla”) filed a Certificate of Elimination (the “Certificate of Elimination”) with the Secretary of State of the State of Delaware with respect to the Company’s Series A Junior Preferred Stock, par value $0.0001 per share (the “Series A Junior Preferred Stock”), following the redemption of the one (1) issued and outstanding share of Series A Junior Preferred Stock (the “Series A Preferred Share”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1826892/000119312526031942/0001193125-26-031942-index.htm","comparable_excerpt":"On April 28, 2026, the Company filed Articles of Amendment to its Articles of Incorporation with the Florida Division of Corporations creating and authorizing 4,000 shares of Series D Preferred Stock and 4,000 shares of Series E Preferred Stock.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1649739/000164973926000020/0001649739-26-000020-index.htm"}},{"accession":"0001185185-26-002273","ticker":"DGAC","company_name":"DISCIPLINED GROWTH ACQUISITION Corp","filed_at":"2026-06-01T20:15:34+00:00","headline":"Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-26-002273","json":"https://secwatch.observer/filing/0001185185-26-002273.json","markdown":"https://secwatch.observer/filing/0001185185-26-002273.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/0001185185-26-002273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/dgac8k052926.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On January 30, 2026, BioAtla, Inc. (the “Company” or “BioAtla”) filed a Certificate of Elimination (the “Certificate of Elimination”) with the Secretary of State of the State of Delaware with respect to the Company’s Series A Junior Preferred Stock, par value $0.0001 per share (the “Series A Junior Preferred Stock”), following the redemption of the one (1) issued and outstanding share of Series A Junior Preferred Stock (the “Series A Preferred Share”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1826892/000119312526031942/0001193125-26-031942-index.htm","comparable_excerpt":"On May 26, 2026, in connection with the IPO, the Company filed its amended and restated memorandum and articles of association (the “Amended and Restated Memorandum and Articles of Association”) with the Cayman Islands Registrar of Companies, which was effective on May 26, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/0001185185-26-002273-index.htm"}},{"accession":"0001703056-26-000078","ticker":"ADT","company_name":"ADT Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Apollo sells all 102M ADT shares; ADT repurchases 29.1M shares in $1.5B plan","event_type":"other_material","sec_items":["5.02","5.03","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001703056-26-000078","json":"https://secwatch.observer/filing/0001703056-26-000078.json","markdown":"https://secwatch.observer/filing/0001703056-26-000078.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703056/000170305626000078/0001703056-26-000078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703056/000170305626000078/adt-20260504.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On January 30, 2026, BioAtla, Inc. (the “Company” or “BioAtla”) filed a Certificate of Elimination (the “Certificate of Elimination”) with the Secretary of State of the State of Delaware with respect to the Company’s Series A Junior Preferred Stock, par value $0.0001 per share (the “Series A Junior Preferred Stock”), following the redemption of the one (1) issued and outstanding share of Series A Junior Preferred Stock (the “Series A Preferred Share”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1826892/000119312526031942/0001193125-26-031942-index.htm","comparable_excerpt":"On May 8, 2026, the Board approved an amendment and restatement of the Company’s Amended and Restated Bylaws, dated as of September 15, 2023 (as amended, the “ Bylaws ”), to remove references related to Apollo and the Amended and Restated Stockholders Agreement, dated December 14, 2018, between the Company, Prime Security Services TopCo Parent, L.P., and the Co-Investors.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1703056/000170305626000078/0001703056-26-000078-index.htm"}},{"accession":"0001213900-26-052459","ticker":"QLEP","company_name":"Quantum Leap Acquisition Corp","filed_at":"2026-05-06T23:59:59+00:00","headline":"Quantum Leap Acquisition Corp closes $200M SPAC IPO on NYSE","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-052459","json":"https://secwatch.observer/filing/0001213900-26-052459.json","markdown":"https://secwatch.observer/filing/0001213900-26-052459.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2102155/000121390026052459/0001213900-26-052459-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2102155/000121390026052459/ea0289253-8k_quantum.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On January 30, 2026, BioAtla, Inc. (the “Company” or “BioAtla”) filed a Certificate of Elimination (the “Certificate of Elimination”) with the Secretary of State of the State of Delaware with respect to the Company’s Series A Junior Preferred Stock, par value $0.0001 per share (the “Series A Junior Preferred Stock”), following the redemption of the one (1) issued and outstanding share of Series A Junior Preferred Stock (the “Series A Preferred Share”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1826892/000119312526031942/0001193125-26-031942-index.htm","comparable_excerpt":"In connection with the IPO, the Company filed its amended and restated memorandum and articles of association (the “Amended and Restated Memorandum and Articles of Association”) with the Cayman Islands Registrar of Companies. The Amended and Restated Memorandum and Articles of Association have an effective date of April 29, 2026, being the date on which the special resolution to adopt the Amended and Restated Memorandum and Articles of Association was passed.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2102155/000121390026052459/0001213900-26-052459-index.htm"}},{"accession":"0001829126-26-004565","ticker":"MCAH","company_name":"Mountain Crest Acquisition 6 Corp.","filed_at":"2026-05-05T23:59:59+00:00","headline":"Mountain Crest Acquisition 6 Corp. closes $60M IPO; units start trading April 30","event_type":"other_material","sec_items":["1.01","3.02","5.03","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-004565","json":"https://secwatch.observer/filing/0001829126-26-004565.json","markdown":"https://secwatch.observer/filing/0001829126-26-004565.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2109876/000182912626004565/0001829126-26-004565-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2109876/000182912626004565/mountaincrest6_8k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On January 30, 2026, BioAtla, Inc. (the “Company” or “BioAtla”) filed a Certificate of Elimination (the “Certificate of Elimination”) with the Secretary of State of the State of Delaware with respect to the Company’s Series A Junior Preferred Stock, par value $0.0001 per share (the “Series A Junior Preferred Stock”), following the redemption of the one (1) issued and outstanding share of Series A Junior Preferred Stock (the “Series A Preferred Share”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1826892/000119312526031942/0001193125-26-031942-index.htm","comparable_excerpt":"On April 29, 2026, in connection with the IPO, the Company filed its Amended and Restated Memorandum and Articles of Association, as described in the Registration Statement, with the Registry of Corporate Affairs of British Virgin Islands.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2109876/000182912626004565/0001829126-26-004565-index.htm"}},{"accession":"0001104659-26-054940","ticker":"MRKR","company_name":"Marker Therapeutics, Inc.","filed_at":"2026-05-04T23:59:59+00:00","headline":"Marker Therapeutics shareholders approve increase in authorized shares from 30M to 130M","event_type":"other_material","sec_items":["5.03","5.07","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 5.07, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-054940","json":"https://secwatch.observer/filing/0001104659-26-054940.json","markdown":"https://secwatch.observer/filing/0001104659-26-054940.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465926054940/0001104659-26-054940-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465926054940/tm2613511d1_8k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On January 30, 2026, BioAtla, Inc. (the “Company” or “BioAtla”) filed a Certificate of Elimination (the “Certificate of Elimination”) with the Secretary of State of the State of Delaware with respect to the Company’s Series A Junior Preferred Stock, par value $0.0001 per share (the “Series A Junior Preferred Stock”), following the redemption of the one (1) issued and outstanding share of Series A Junior Preferred Stock (the “Series A Preferred Share”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1826892/000119312526031942/0001193125-26-031942-index.htm","comparable_excerpt":"the Company’s stockholders approved an amendment to the Company’s Certificate of Incorporation, as amended, to increase the number of authorized shares of our Common Stock from 30,000,000 shares of Common Stock to 130,000,000 shares of Common Stock (the “ Charter Amendment ”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465926054940/0001104659-26-054940-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}